Walleye Capital
MYGN icon

Walleye Capital’s Myriad Genetics MYGN Stock Holding History

Walleye Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
+464,647
New +$2.11M 0.01% 1288
2026
Q1 		– Sell
-677,176
Closed -$4.16M – 4758
2025
Q4 		$4.16M Buy
677,176
+277,319
+69% +$2.01M 0.01% 1279
2025
Q3 		$2.89M Buy
399,857
+354,385
+779% +$2.1M 0.01% 1317
2025
Q2 		$241K Sell
45,472
-141,130
-76% -$834K ﹤0.01% 3217
2025
Q1 		$1.66M Buy
+186,602
New +$2.24M 0.01% 1562
2024
Q1 		– Sell
-17,228
Closed -$330K – 5720
2023
Q4 		$330K Buy
17,228
+16,907
+5,267% +$292K ﹤0.01% 3300
2023
Q3 		$5.15K Buy
+321
New +$6.11K ﹤0.01% 4584
2023
Q2 		– Sell
-26,149
Closed -$607K – 4685
2023
Q1 		$607K Sell
26,149
-12,977
-33% -$264K 0.01% 1550
2022
Q4 		$568K Buy
39,126
+17,880
+84% +$333K 0.01% 1363
2022
Q3 		$405K Buy
+21,246
New +$488K 0.01% 1612
2022
Q2 		– Sell
-15,852
Closed -$399K – 2592
2022
Q1 		$399K Buy
+15,852
New +$406K 0.01% 1128
2021
Q4 		– Sell
-7,381
Closed -$238K – 2240
2021
Q3 		$238K Buy
+7,381
New +$245K 0.01% 1128
2020
Q4 		– Sell
-46,114
Closed -$601K – 1047
2020
Q3 		$601K Buy
46,114
+24,288
+111% +$307K 0.07% 335
2020
Q2 		$248K Sell
21,826
-3,154
-13% -$44.8K 0.06% 375
2020
Q1 		$358K Buy
24,980
+24,722
+9,582% +$522K 0.08% 298
2019
Q4 		$7K Buy
258
+158
+158% +$4.35K ﹤0.01% 1666
2019
Q3 		$3K Buy
+100
New +$2.91K ﹤0.01% 1825
2019
Q2 		– Sell
-300
Closed -$10K – 1931
2019
Q1 		$10K Buy
+300
New +$9.13K ﹤0.01% 1404

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Capital's MYGN Position: Q2 2026 in Review

Walleye Capital opened a new position in Myriad Genetics (MYGN) in Q2 2026: 464,647 shares worth $2.65M. The stake represents 0.01% of the portfolio and ranks #1288 among its holdings. This is a return to the name: Walleye Capital previously reported a position in MYGN as recently as Q4 2025.

Walleye Capital first reported a position in MYGN in Q1 2019 and has held it in 18 quarters since. The position peaked at $4.16M in Q4 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Walleye Capital held 464,647 shares of Myriad Genetics worth $2.65M as of Q2 2026.
  • Myriad Genetics was a new Walleye Capital position in Q2 2026.
  • Myriad Genetics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1288 holding.
  • Walleye Capital first reported a position in Myriad Genetics in Q1 2019 and has held it in 18 quarters since.
  • Walleye Capital's Myriad Genetics position peaked at $4.16M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.